From its 1886 founding to a $94.2B revenue powerhouse, Johnson & Johnson has remade itself into a focused pharmaceutical and medtech company.
The Company That Defined Healthcare
Johnson & Johnson has been part of American life longer than most institutions people take for granted. Founded in 1886 and headquartered in New Brunswick, New Jersey, it has grown into what its own description calls the world's largest and most diverse healthcare firm — a title backed up by numbers that are genuinely hard to put in perspective.
With roughly 140,800 employees worldwide and a market capitalization of $560.3 billion, J&J operates at a scale few companies in any industry can match.
A Company Rebuilt From the Inside Out
The J&J of today looks meaningfully different from the one investors watched for decades. In 2023, the company divested its consumer business — the segment that housed many of its household-name products — spinning it off as a separate company called Kenvue. That decision was deliberate. What remains are two sharply focused divisions: innovative medicine and medtech.
This isn't a trimming of ambition. It's a concentration of it.
What the Two Divisions Actually Do
Innovative Medicine
Following restructuring in 2023 and 2024, J&J's drug division now focuses on three core therapeutic areas: immunology, oncology, and neurology. These are among the most scientifically complex — and commercially significant — fields in modern medicine.
Medtech
The medtech arm covers the devices, surgical tools, and technologies that operate alongside the pharmaceutical side. Together, the two divisions account for all of J&J's sales following the Kenvue spinoff.
Revenue Scale and Where It Comes From
For the fiscal year 2025, Johnson & Johnson reported revenue of $94.2 billion. Just over half of that total was generated inside the United States, with the remainder coming from international markets — a geographic spread that gives the company resilience against any single economy's fluctuations.
To put the growth in context: revenue grew 14% from FY2020 to FY2025. For a company already operating at this size, that kind of sustained expansion is a meaningful signal about the underlying demand for its products.
Profitability That Stands Apart
Revenue is one thing. What J&J does with that revenue is another. The company posted net income of $26.8 billion in FY2025 — a net margin of 28.5%. That means for roughly every four dollars that comes in the door, more than one dollar becomes profit.
The gross margin sits at 67.9%, which reflects the premium economics of pharmaceutical and medtech products compared to most other industries. Total assets stand at $199.2 billion, underscoring the enormous infrastructure and intellectual property base behind those numbers.
How the Market Values the Business
J&J trades on the NYSE under the ticker JNJ, and its shares were recently quoted at $254.66 (15-minute delayed). The stock is trading near its 52-week high.
The market values the company at a price-to-earnings ratio of 23.1 — a figure that reflects investor confidence in the durability of J&J's earnings stream. The company also pays a dividend yielding approximately 2.1% annually, a feature that has long attracted shareholders who value steady income alongside growth.
A Long View on an Old Company
J&J went public in September 1944 — meaning it has been a publicly traded company for more than eight decades. Over that span, it has navigated wars, recessions, regulatory upheavals, and fundamental shifts in medicine. The 2023–2024 restructuring is simply the latest chapter in a story of deliberate reinvention.
For a general reader, the clearest takeaway is straightforward: this is a company that has found a way to grow larger, sharper, and more profitable at the same time — no small feat at its scale.
This article is factual reporting drawn from public filings and market data and is not investment advice.
